Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
A legfontosabb adatok
- Ki végzi
- ShanShan Li
- Hol
- Changzhou, Dongying, Huai'an, Jiaozuo, Lanzhou, Lianyungang, Nanjing, Ningxiang, Shanghai, Shangxi, Shenzhen, Shiyan, Suzhou, Xi’an és Xuzhou (Kína)Mind a 19 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 300 fő, tervezett
- Kezdés
- 2026. júl. 2.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- 1.5% Ruxolitinib Phosphate Cream (Opzelura)
- Corticosteroid Therapy
- A regiszteradat frissítve
- 2026. szeptember 8.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people aged 12 years and older with active, spreading non-segmental vitiligo on the face. They will use Ruxolitinib cream together with corticosteroid medicine.
- Életkor
- 12 years and older
- Nem
- All sexes
- A betegség stádiuma
- Non-segmental vitiligo on the face that is active or spreading, covering 10% or less of the body surface. Activity is shown by a VIDA score of 3 or more, typical skin signs, or larger patches under Wood's lamp than seen by eye.
A részvétel fő kizáró okai
- Other types of vitiligo, such as segmental vitiligo, or stable vitiligo
- Other skin conditions causing white patches
- Patches where more than 1/3 of the hair is white
- Unable to take corticosteroid medicine by mouth or injection, or allergy to the study medicines
- End-stage kidney disease or being on dialysis
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 12 years at the time of signing informed consent
- Clinical diagnosis of non-segmental vitiligo with facial involvement, and total body surface area (BSA) depigmentation ≤ 10%
- Diagnosed with progressive/active vitiligo meeting at least one of the following: Vitiligo Disease Activity (VIDA) score ≥ 3; Clinical signs including trichrome vitiligo, confetti-like depigmentation, or Koebner phenomenon; The extent of lesions under Wood's lamp is larger than that visible to the naked eye
- Agrees to have no pregnancy plans and uses effective contraception during the study and up to 4 weeks after the last dose
- Voluntarily signs the informed consent form and agrees to regular follow-up visits
Ki nem vehet részt
- Contraindications to systemic corticosteroid use
- Concurrent participation in other clinical studies
- Co-existing skin depigmentation disorders affecting efficacy evaluation (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus anemicus, chemical leukoderma, tinea versicolor)
- Known hypersensitivity or allergy to the study medications or excipients
- Known end-stage renal disease (ESRD) or currently undergoing renal replacement therapy (e.g., dialysis)
- Any other condition which, in the investigator's judgment, makes the patient unsuitable for the study
- Diagnosis of other clinical forms of vitiligo (e.g., segmental vitiligo)
- Clinically diagnosed with stable vitiligo
- Leukoderma lesions with more than 1/3 white hair, or lesions accompanied by white hair where the investigator assesses the probability of benefit from participating is low based on clinical experience
Helyszínek itt: Kína
- Changzhou First People's HospitalChangzhou, KínaContact: Yu Hua YangToborzás még nem indult
- Dongying People's HospitalDongying, KínaContact: Dr.Wang HaiyingRésztvevőt keres
- The Second People's Hospital of Huai'anHuai'an, KínaContact: Chunsheng YangToborzás még nem indult
- Central Hospital of Jiaozuo Coal Industry (Group) Co., Ltd.Jiaozuo, KínaContact: Dr. Pei GuangdeToborzás még nem indult
- The Second Hospital of Lanzhou UniversityLanzhou, KínaContact: Dr.Wu JinRésztvevőt keres
- The First People's Hospital of LianyungangLianyungang, KínaContact: Wen Long HuToborzás még nem indult
- Nanjing Drum Tower hospitalNanjing, KínaContact: Jun BaoToborzás még nem indult
- U-Family Clinic (Nanjing) Co., Ltd.Nanjing, KínaContact: Hong JiaToborzás még nem indult
- People's Hospital of Ningxia Hui Autonomous RegionNingxiang, KínaContact: Dr.Yang RuiRésztvevőt keres
- Xinhua Hospital Affiliated To Shanghai Jiao tong University School of MedicineShanghai, KínaContact: Pan MengToborzás még nem indult
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese MedicineShanghai, KínaContact: Xin LiRésztvevőt keres
- Changzhi Second People's HospitalShangxi, KínaContact: Dr. Li YufeiToborzás még nem indult
- Shenzhen Hospital of Southern Medical UniversityShenzhen, KínaContact: Dr. Liang YanhuaRésztvevőt keres
- Shenzhen Hospital, Southern Medical UniversityShenzhen, KínaContact: Yanhua LiangToborzás még nem indult
- Shiyan People's Hospital (Hubei University of Medicine Affiliated People's Hospital)Shiyan, KínaContact: Dr. Meng ZudongToborzás még nem indult
- The First Affiliated Hospital of Soochow UniversitySuzhou, KínaContact: Yu Qian ZhuToborzás még nem indult
- The Fourth Affiliated Hospital of Soochow UniversitySuzhou, KínaContact: Xuejun ZhangToborzás még nem indult
- The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, KínaContact: Dr. Mou KuanhouRésztvevőt keres
- Affiliated Hospital of Xuzhou Medical UniversityXuzhou, KínaContact: Guan JiangToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is a prospective, multicenter, real-world observational study to assess the clinical efficacy and safety of topical 1.5% Ruxolitinib phosphate cream used in combination with systemic corticosteroids in a real-world clinical setting. The study plans to observe patients aged 12 years and older with active, progressive non-segmental vitiligo involving the face. All treatments are prescribed based on standard routine clinical care and medical practice guidelines. Participants will apply Ruxolitinib cream twice daily to affected skin areas for up to 24 weeks alongside a standard corticosteroid regimen. The primary goal of the study is to evaluate how many patients achieve a 75% or greater improvement in their facial vitiligo patches after 12 weeks of combined treatment. Safety and side effects will also be closely monitored throughout the 24-week period.
A vizsgált kezelések
- 1.5% Ruxolitinib Phosphate Cream (Opzelura)
- Corticosteroid Therapy
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy and Safety of Ruxolitinib Phosphate Cream Combined With Corticosteroids in Patients With Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. szeptember 8.